These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20067983)

  • 1. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
    Armand-Ugón M; Moncunill G; Gonzalez E; Mena M; Ballana E; Clotet B; Esté JA
    J Antimicrob Chemother; 2010 Mar; 65(3):417-24. PubMed ID: 20067983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
    Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
    J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
    Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
    J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
    Yuan Y; Maeda Y; Terasawa H; Monde K; Harada S; Yusa K
    Virology; 2011 May; 413(2):293-9. PubMed ID: 21440278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
    Soulié C; Malet I; Lambert-Niclot S; Tubiana R; Thévenin M; Simon A; Murphy R; Katlama C; Calvez V; Marcelin AG
    AIDS; 2008 Oct; 22(16):2212-4. PubMed ID: 18832886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
    Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
    Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
    Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline susceptibility of primary HIV-2 to entry inhibitors.
    Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
    Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
    Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
    Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
    Yusa K; Maeda Y; Fujioka A; Monde K; Harada S
    J Biol Chem; 2005 Aug; 280(34):30083-90. PubMed ID: 15983047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.
    Ratcliff AN; Shi W; Arts EJ
    J Virol; 2013 Jan; 87(2):923-34. PubMed ID: 23135713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
    Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
    J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.